Atara Biotherapeutics, Inc.

Atara Biotherapeutics is a clinical-stage biotechnology company developing T-cell immunotherapies targeting cancer and autoimmune diseases. The company is headquartered in Thousand Oaks, California, and operates with a lean workforce of 38 full-time employees. Its primary focus is Tab-cel (tabelecleucel), a T-cell therapy currently in Phase 3 clinical trials for the treatment of Epstein-Barr virus-associated post-transplant lymphoproliferative disease and other EBV-driven malignancies. The company maintains research collaboration agreements with Memorial Sloan Kettering Cancer Center and the Council of the Queensland Institute of Medical Research to support its clinical development activities.

As a development-stage entity, Atara does not currently generate significant revenue from product sales. The company's operations center on advancing its clinical pipeline, with Tab-cel representing the most advanced program. The company was incorporated in Delaware in 2012 and maintains operations in both the United States and the United Kingdom.